

SAN FRANCISCO

CYSTIC FIBROSIS SUMMIT

CURRENT TRENDS AND FUTURE DIRECTIONS

Dear Colleague,

We are pleased to invite you to a very exciting and intensive accredited educational activity designed specifically for physicians and advanced practitioners involved in the management and treatment of patients with cystic fibrosis. During this half-day course, we will discuss the clinical impact of consequential respiratory pathogens, review long-term treatment data, examine the role of CFTR modulators, and discuss the impact of clinical comorbidities such as nutritional deficits and mental health issues.

We will also interview a patient with cystic fibrosis and then collaborate on strategies to improve patient and family education, ensure smooth transitioning from pediatric to adult care, and develop techniques to help our patients improve their adherence to treatment.

This educational activity is designed to be highly interactive in nature and is limited to a small number of participants. Please plan to register soon. We look forward to seeing you!



Carlos E. Milla
Program Chairman



Carlos E. Milla, MD

Associate Professor of Pediatrics—Pulmonary Medicine
Director, The Stanford Cystic Fibrosis Center
Associate Director for Translational Research
Center for Excellence in Pulmonary Biology
Stanford University School of Medicine
Palo Alto, CA



Peter J. Mogayzel, Jr., MD, PhD, MBA

Professor of Pediatrics
Interim Director, Eudowood Division of Pediatric
Respiratory Sciences
Director, Cystic Fibrosis Center
Medical Director, Pediatric Specialty Clinic
Johns Hopkins Cystic Fibrosis Center
Baltimore, MD



Brian M. Morrissey, MD

Professor, Internal Medicine
Cystic Fibrosis Program Director
University of California, Davis
Sacramento, CA



PROGRAM AGENDA

- 8:00 am–8:30 am **CME Registration / Continental Breakfast**
- 8:30 am–8:45 am **Welcome and Introductions**
Carlos E. Milla, MD
- 8:45 am–9:30 am **Real World Experience: A Patient's Perspective—Patient Interview**
- 9:30 am–10:00 am **The Current Lay of the Land**
Carlos E. Milla, MD
- 10:00 am–10:15 am **Break**
- 10:15 am–11:15 am **The Big Picture—Infection Prevention to Chronic Suppression**
Peter J. Mogayzel, Jr., MD, PhD
- 11:15 am–12:00 pm **CFTR Modulation—Where We Are and Where We Are Headed**
Carlos E. Milla, MD
- 12:00 pm–1:15 pm **Lunch / Breakout Session**
All Faculty
- 1:15 pm–1:45 pm **Pediatric to Adult Care—Easing the Transition**
Brian M. Morrissey, MD
- 1:45 pm–2:15 pm **Adherence—Overcoming Obstacles on the Road to Success**
Peter J. Mogayzel, Jr., MD, PhD
- 2:15 pm–2:30 pm **Concluding Remarks and Evaluation**
Carlos E. Milla, MD

LEARNING OBJECTIVES

As a result of attending this program, participants will be able to:

- Describe the clinical relevance and changing epidemiology of consequential respiratory pathogens.
- Select aerosolized antibiotics by comparing safety, efficacy, and long-term study data, and monitor outcomes for necessary treatment adjustments.
- Describe the evolution of CFTR modulators and decide when they are an appropriate addition to the treatment plan based on patient specific criteria including mutation analysis.
- Assess the impact of nutrition management, mental health screening, and treatment of comorbid conditions on overall patient outcomes.
- Outline current recommendations for transfer from the pediatric to the adult care setting.
- Appreciate the number and complexity of treatments and involve patients and/or family in treatment management decisions to improve adherence.
- Implement best practices to prevent the incidence and spread of infection both in the clinical setting and via patient/caregiver education for the non-clinical setting.

ACCREDITATION



ABcomm, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

ABcomm, Inc. designates this educational activity for a maximum of **5.5 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must complete and submit an activity evaluation form in order to receive a certificate of credit. Certificates will be emailed to participants 4-6 weeks after the activity.

SAN FRANCISCO

CYSTIC FIBROSIS SUMMIT

CURRENT TRENDS AND FUTURE DIRECTIONS

Saturday, September 23, 2017 • 8:00 am–2:30 pm

Parc 55 San Francisco • 55 Cyril Magnin St.
San Francisco, CA

DISCLOSURE STATEMENT

It is the policy and practice of ABcomm, Inc. to resolve all potential conflicts of interest prior to activities. This information will be made available to participants at the beginning of the activity.

REGISTRATION PROCEDURE

Registrations will be accepted through **Friday, September 15, 2017** or until the maximum enrollment is reached. Enrollment is limited to 25 participants.

Registrations can be submitted using one of the following methods:

ONLINE: Go to www.cfsummitsanfrancisco.eventbrite.com

TELEPHONE: Contact us at (217) 607-1285 during regular business hours.

FAX / SCAN: Complete the written application form and email to LValentine@ABcomminc.com or fax to (866) 266-9741.

MAIL: Send application form with check payable to ABcomm, Inc. or credit card information to ABcomm, Inc., PO Box 7046, Champaign, IL 61826.

FEE

The registration fee for *Cystic Fibrosis Summit: Current Trends and Future Directions* is \$30. This fee includes all educational materials, planned group meal functions, and CME certificate. Participants are responsible for their own travel, parking, and lodging expenses.

REFUND POLICY

Your registration fee will be fully refunded if your application is not accepted due to space limitations. In the event that you need to cancel, one-half of your registration fee (\$15) will be refunded if written notification is received by September 15, 2017.

LODGING

Overnight accommodations at Parc 55 are available at preferred rates from \$212 per night plus taxes. Please make reservations at <http://bit.ly/2smtY7N> or call for reservations at (415) 392-8000 by September 1, 2017 and request the Cystic Fibrosis Summit rate. If you need a reservation after September 1, 2017, please contact Linda Valentine at (217) 607-1285. A limited number of rooms are available, so please inquire early.

Parc 55 San Francisco

55 Cyril Magnin St.
San Francisco, CA
(415) 392-8000

For a list of parking garages near the Parc 55 Hotel, please email Linda Valentine at LValentine@ABcomminc.com.



REGISTER ONLINE AT

www.cfsummitsanfrancisco.eventbrite.com



Register online at
www.cfsummitsanfrancisco.eventbrite.com

SAN FRANCISCO

CYSTIC FIBROSIS SUMMIT

CURRENT TRENDS AND FUTURE DIRECTIONS

REGISTRATION FORM

FIRST NAME	LAST NAME	DEGREE(S)
TITLE		INSTITUTION
ADDRESS	CITY	STATE
ZIP	PHONE	EMAIL

PAYMENT INFORMATION

☐ Visa ☐ MasterCard ☐ American Express ☐ Discover ☐ Check (mailed with registration form)

CARD NUMBER	EXPIRATION DATE	3-4 DIGIT SECURITY CODE
-------------	-----------------	-------------------------

BILLING ADDRESS

OTHER INFORMATION

WHAT IS YOUR AREA OF SPECIALTY? ☐ PULMONOLOGY ☐ PEDIATRIC PULMONOLOGY ☐ PEDIATRICS
☐ INTERNAL MEDICINE ☐ CRITICAL CARE ☐ OTHER _____

ARE YOU BOARD CERTIFIED? ☐ YES ☐ NO YEARS IN PRACTICE _____

ON AVERAGE, HOW MANY PATIENTS WITH CF DO YOU TREAT PER WEEK? _____

HOW DID YOU LEARN ABOUT THIS ACTIVITY? ☐ EMAIL ☐ BROCHURE OR LETTER IN MAIL ☐ COLLEAGUE

WHAT DO YOU HOPE TO GAIN FROM ATTENDING THIS ACTIVITY?

IDENTIFY THE BIGGEST BARRIER TO IMPLEMENTING CHANGES IN YOUR PRACTICE:

IF YOU HAVE ANY SPECIAL NEEDS OR DIETARY RESTRICTIONS FOR THIS ACTIVITY, PLEASE SPECIFY:

REGISTRATION DEADLINE: FRIDAY, SEPTEMBER 15, 2017

SAN FRANCISCO

**CYSTIC
FIBROSIS** SUMMIT

CURRENT TRENDS AND
FUTURE DIRECTIONS

ABcomm, Inc.
PO Box 7046
Champaign, IL 61826-7046

Saturday, September 23, 2017
8:00 am – 2:30 pm
Parc 55 San Francisco
San Francisco, CA



SAN FRANCISCO

**CYSTIC
FIBROSIS** SUMMIT

CURRENT TRENDS AND
FUTURE DIRECTIONS



Saturday, September 23, 2017 • 8:00 am – 2:30 pm
Parc 55 San Francisco
San Francisco, CA

Medical Education
ABCOMM, INC.
Provided by ABcomm, Inc.

Supported by an independent educational grant from Gilead Sciences Medical Affairs.